Đáp ứng của phác đồ pemetrexed đơn trị trên bệnh nhân ung thư phổi không tế bào nhỏ giai đoạn IIIB - IV cao tuổi tại bệnh viện Hữu Nghị=Treatment response to pemetrexed monotherapy in elderly patients with stage III-IV non-small cell lung cancer at Friendship hospital

0 Người đánh giá. Xếp hạng trung bình 0

Tác giả: Thị Khánh Tâm Lê, Thanh Huyền Vũ

Ngôn ngữ: vie

Ký hiệu phân loại:

Thông tin xuất bản: Tạp chí Y học Việt Nam (Tổng hội Y học Việt Nam), 2024

Mô tả vật lý: tr.28-34

Bộ sưu tập: Metadata

ID: 478105

Thêm vào giỏ

Đánh giá đáp ứng của phác đồ pemetrexed trên bệnh nhân ung thư phổi không tế bào nhỏ giai đoạn IIIB- IV cao tuổi tại bệnh viện Hữu Nghị. Đối tượng và phương pháp nghiên cứu: Nghiên cứu mô tả hồi cứu trên 38 bệnh nhân cao tuổi ung thư phổi không tế bào nhỏ giai đoạn IIIB-IV tại bệnh viện Hữu Nghị từ tháng 1/2019 đến tháng 1/2023. Kết quả: Tuổi trung bình của nhóm bệnh nhân là 70,71 ± 4,674, thấp nhất là 65 tuổi, cao nhất là 87 tuổi, bệnh nhân trên 70 tuổi chiếm 86,8%. Tỉ lệ bệnh nhân giảm triệu chứng cơ năng là 52,6%, tỉ lệ bệnh nhân đáp ứng cơ năng hoàn toàn 7,9%. Tỉ lệ kiểm soát bệnh 65,8%, có 34,3% bệnh nhân tiến triển trên chẩn đoán hình ảnh. Kết luận: Phác đồ pemetrexed đơn trị là phác đồ có hiệu quả cho các bệnh nhân ung thư phổi không tế bào nhỏ giai đoạn IIIB- IV cao tuổi.To evaluate the treatment response of elderly patients with stage IIIB-IV non-small cell lung cancer receiving pemetrexed monotherapy at Friendship Hospital. Subjects and methods: A retrospective descriptive study on 38 elderly patients with stage IIIB - IV NSCLC who received pemetrexed monotherapy at Friendship Hospital from January 2019 to January 2023. Results: Mean age: 70.71 ± 4.674 (ranging 65 -87)
52.6% of patients achieved a clinical symptom response, of which 7.9% responded completely. The disease control rate was 65.8%, and disease progression was observed in 34.3% of patients. Conclusion: Pemetrexed monotherapy is an effective chemotherapy for elderly patients with stage IIIB-IV NSCLC.

1. Đọc trực tuyến

1. Đọc trực tuyến

Tạo bộ sưu tập với mã QR